Optimize drug therapy and monitor patient adherence.
High Performance Liquid Chromatography/Tandem Mass Spectrometry
New York DOH Approval Status
Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration.
Plain red. Also acceptable: Lavender (K2 or K3EDTA) or pink (K2EDTA).
Separate serum or plasma from cells within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Refrigerated: Also acceptable: Room temperature or frozen.
Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).
Ambient: 15 days; Refrigerated: 15 days; Frozen: 15 days
Effective November 15, 2021
|Therapeutic Range:||Not well established. Suggested range 1.0-10.0 µg/mL|
|Toxic Level||Greater than or equal to 20 µg/mL|
Lacosamide is an anticonvulsant drug indicated for adjunctive therapy for partial-onset seizures. The therapeutic range is based on serum, predose (trough) draw collection at steady-state concentration. Adverse effects may include dizziness, fatigue, nausea, vomiting, blurred vision, and tremor.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|2003183||Lacosamide, Serum or Plasma||59297-2|
- Lacosamide blood level
- vimpat blood level